menu

SSc-ILD: The Importance of Early Diagnosis, Patient Centered Communication and Evidence Based Treatment

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

SSc-ILD: The Importance of Early Diagnosis, Patient Centered Communication and Evidence Based Treatment

close
1.00 credits
1 Hour
SSc-ILD: The Importance of Early Diagnosis, Patient Centered Communication and Evidence Based Treatment
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    The goal of this activity is to improve the awareness, knowledge, and competency of pulmonologists, rheumatologists, radiologists, dermatologists and primary care physicians in the diagnosis, treatment and a multidisciplinary approach to the longitudinal management of Systemic Sclerosis Interstitial Lung Disease (SSc-ILD).

  • Disclosure of Conflicts of Interest

    Amy Olson, MD discloses that she is on an Advisory Board for Boehringer Ingelheim, on the Board of Directors for MedGraphics as well as a speaker for Boehringer Ingelheim, Genentech, PeerView, Pilot/France Foundation and Vindico.  Dr. Olson also conducts research for Boehringer Ingelheim.

    Virginia Steen, MD discloses that she is on an Advisory Board for Boehringer Ingelheim and a Consultant for Boehringer Ingelheim, CSL Behring and Eicos.

    Zulma Yunt, MD discloses that she is a Speaker for Boehringer Ingelheim.

    None of the following planners or reviewers have any relevant financial relationships to disclose: Amen Sergew, MD, Michael Mohning, MD, Andrea Harshman, MHA, CHCP, CMP-HC, Meghan Brenner, MA, Mandy Comeau, the patient featured in the video segment.

  • Target Audience

    Pulmonologists, Radiologists, and Pathologists, as well as Primary Care Physicians, Registered Nurses, Nurse Practitioners, and Physician Assistants.

  • Learning Objectives

    1. Apply best practices in diagnosis based on clinical symptoms, pathophysiology and disease course of SSc-ILD.
    2. Utilize evidence-based decision making in the selection of treatments for patients with SSc-ILD.
    3. Apply strategies for longitudinal management of SSc-ILD using a multidisciplinary approach and patient-centered communication.
  • Accreditation and Credit Designation Statements

    Physicians:  National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    National Jewish Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Provider approved by the California Board of Registered Nursing, Provider Number 12724 for 1.0 nursing contact hours.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    The goal of this activity is to improve the awareness, knowledge, and competency of pulmonologists, rheumatologists, radiologists, dermatologists and primary care physicians in the diagnosis, treatment and a multidisciplinary approach to the longitudinal management of Systemic Sclerosis Interstitial Lung Disease (SSc-ILD).

  • Disclosure of Conflicts of Interest

    Amy Olson, MD discloses that she is on an Advisory Board for Boehringer Ingelheim, on the Board of Directors for MedGraphics as well as a speaker for Boehringer Ingelheim, Genentech, PeerView, Pilot/France Foundation and Vindico.  Dr. Olson also conducts research for Boehringer Ingelheim.

    Virginia Steen, MD discloses that she is on an Advisory Board for Boehringer Ingelheim and a Consultant for Boehringer Ingelheim, CSL Behring and Eicos.

    Zulma Yunt, MD discloses that she is a Speaker for Boehringer Ingelheim.

    None of the following planners or reviewers have any relevant financial relationships to disclose: Amen Sergew, MD, Michael Mohning, MD, Andrea Harshman, MHA, CHCP, CMP-HC, Meghan Brenner, MA, Mandy Comeau, the patient featured in the video segment.

  • Target Audience

    Pulmonologists, Radiologists, and Pathologists, as well as Primary Care Physicians, Registered Nurses, Nurse Practitioners, and Physician Assistants.

  • Learning Objectives

    1. Apply best practices in diagnosis based on clinical symptoms, pathophysiology and disease course of SSc-ILD.
    2. Utilize evidence-based decision making in the selection of treatments for patients with SSc-ILD.
    3. Apply strategies for longitudinal management of SSc-ILD using a multidisciplinary approach and patient-centered communication.
  • Accreditation and Credit Designation Statements

    Physicians:  National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    National Jewish Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Provider approved by the California Board of Registered Nursing, Provider Number 12724 for 1.0 nursing contact hours.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 3/7/21